Therapy of non-small cell lung cancer (NSCLC) is undergoing a revolution: in early stage NSCLC surgical treatment possibilities have been enhanced by the introduction of video-assisted thoracic surgery (VATS) offering patients relevant benefits including less pain and a better quality of life (1). For advanced stages the implementation of targeted and immune-therapies have just begun to emerge and are about to replace classical chemotherapy as first line treatment option in selected cases (2,3). These developments will significantly change established treatment algorithms.
展开▼
